PCYT2 and metabolic dysfunction-associated steatohepatitis: CDP-Etn supplementation has been reported to alleviate PCYT2 deficiency engendering age-dependent and insulin-resistant non-alcoholic steatohepatitis to improve patient prognosis [20,29–31].